DOCSLIB.ORG

Administration of Drug to Reach a Given Clinical Endpoint: Treatment Or Prevention of Disease Therapeutic Dose Depends On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Administration of Drug to Reach a Given Clinical Endpoint: Treatment Or Prevention of Disease Therapeutic Dose Depends On 4/24/2018 .Administration of drug to reach a given clinical endpoint: treatment or prevention of disease .Therapeutic dose depends on patient age, Part One: General Pharmacology Principles; sex, race, other meds taken and other medical Drug Delivery Systems; Topical Anesthetics; conditions Viscoelastics; Dilating Solutions for Cataract Surgery Christopher J. McDevitt, M.D. Eye drops avoid first pass metabolism by the liver and . Pharmacokinetics: . Pharmacodynamics: increases systemic bioavailability . Substances cycling through . Biological and chemical effects biological tissue of chemical on the biological . Systemic toxicity may be more then expected from topical system . Absorption dose . Tissue receptor for the drug . Distribution . Neonates, infants have less developed drug metabolism . Metabolism . Intracellular changes initiated by the drug and excretion . Excretion . Categorized by the receptor . Local toxicity is more common than systemic toxicity with . With the dose of the med these for the drug i.e. alpha agonist determine the bioavailability at type I (IgE) mediated hypersensitivity or delayed reaction the site of intended action type 4 . Preservatives can be toxic to ocular surface can enhance . Disappearing preservatives theoretically should have no corneal permeability. Common preservatives in ophthalmic toxicity to the corneal surface preparations: . Preservative dissipates with exposure to light or to ions in . Benzalkonium chloride (BAK) the tear film . Thimerosal . Disappearing preservatives: oxychloro complex breaks . Chlorobutanol down into sodium chloride and water. Sodium perborate . Parahydroxybenzoates breaks down to hydrogen peroxide then to hydrogen and . Aromatic alcohols water 1 4/24/2018 . Need to be lipophilic and . .Ionic buffer with borate, sorbitol, propylene glycol hydrophobic epithelium and Solutions vs suspensions: and zinc breaks down on exposure to tear film endothelium; stroma is hydrophilic solubility in the tear film meds and lipophobic with poor water solubility are cations . Meds must be lipophilic and formulated as suspensions hydrophilic .Poly quad (polyquaternium-1): detergent that is . Lipid solubility to water solubility . Viscosity increases the repelled by corneal epithelium ratio retention of the such as Timolol . Non-ionic pass through cell GFS membranes more readily . Preservative-free single-use preparations are also . pH of medication can be changed to . Limits to the amount of increase the percentage in a non- viscosity: sticky sensation may an alternative ionic form of the medication to increase absorption result and may cause surface irritation . Less lean body mass . Extends the half life of most mediations in the elderly . Less body water and albumin . The action of the drug is . Higher relative percentage of potentiated adipose tissue . Therapeutic and toxic effects of . Results in alterations in tissue a medication may be altered binding and drug distribution by the aging process . Take multiple meds that can independent of the drug affect metabolism dosage . Hepatic and renal systems also Topical, Systemic, Periocular, decrease with age Intracameral, Intravitreal . Concentration of the medication .Subconjunctival and sub-Tenon injection allow . Solubility drugs to bypass corneal and conjunctival epithelial . Viscosity barriers and enter sclera and intraocular by . Lipid solubility . Drug’s pH concentration gradient . Ionic form .Intraocular injections: intracameral (into the . Molecular size anterior segment) and intravitreal: instantly delivers . Chemical structure effective concentration to target site . Surfactants . Reflex tearing 2 4/24/2018 . Blood-ocular barrier: vascular endothelium of retina non-fenestrated with tight junctions . Choroid and ciliary body sequestered from delivery of systemic meds . Drugs with high lipid solubility i.e. chloramphenicol penetrates eye much better that penicillin . Binding of drug with plasma proteins limits free serum levels and must be exceeded . Bolus IV exceeds the binding capacity of plasma proteins leading to higher intraocular levels of drug when compared with IV drip . Oral meds: Diamox in sustained release sequel reduces .Encapsulated cell technology IOP for 20 hours compared with 10 hours for the standard Diamox tablet .Nanostructure tethadur: using nanoparticles to protect active molecules and provide sustained . Ocusert: pilocarpine used in past delivery; Nano-capsules, Nano-spheres, Nano- . Surgical implant Ganciclovir for 5-8 months; fluocinolone suspension and emulsions acetonide steroid .Refillable reservoir . Dexamethasone biodegradable polymer matrix (NOVADUR) injection into vitreous cavity Ozurdex for .Refillable pump diabetic macular edema . Porcine scleral tissue extracted and . Poorly tolerated as they are . soak contact lens in drug . Use molecular imprinting molded into contact lens-soak uncomfortable shields . Monomers in contact lens technique wherein contact . Treatment of bacterial keratitis in lens hydrogels are . Useful in delivery system prolonging early stages hydrogels with target contact time between drug and drugs organized for high affinity cornea binding of the drug . Drugs incorporated into collagen . Drug –loaded colloidal matrix during manufacturing process nanoparticles into the or absorbed into the shield at rehydration or applied topically matrix of the contact lens while on the eye . Shield dissolves in 12, 24 or 72 hours 3 4/24/2018 . Punctal plug mediated delivery systems . Genetically engineered . Application for AMD with . Core with drug cells designed to anti-VEGF, anti-PDGF overproduce protein of . Cap with pores which the drug is released . ECT with VEGF receptor interest decoy in clinical trials . Advantage: dose reduction, controlled release patient . Multi-year implant have demonstrated compliance viability beneficial decrease in . Encapsulated in retinal thickness . Iontophoresis: moving charged molecules by electric nonbiodegradable system current; limited by discomfort and ocular damage . Injectable peptide microparticule . Eggs in and egg carton analogy adsorption of target molecule into customized molecular pores . Release from matrix over periods of days to months . Peptide is mixed with Tethadur particles and administered to patient . Inactive derivatives are activated by enzymes inside the . Pharmacy compounding accreditation board (PCAB) eye provide evidence of adherence to compounding standards . Ester and amide prodrugs are hydrolyzed by esterase and . State and federal licensing amidases as they penetrate cornea and conjunctiva . Appropriate training aseptic compounding meeting USP . Prodrug is more permeable to cornea than active med. guidelines . Prostaglandin analogues such as latanoprost, travoprost, . www.pcab.org/accredited-pharmacies unoprostone (esters prodrugs) and bimatoprost (amide) . Record lot number of medication and lot number of syringes in patient record 4 4/24/2018 Tetracaine, lidocaine gel . Proparacaine, tetracaine . Lidocaine 4% for injection can be used topically as well as lidocaine 2% jelly . Bupivacaine 0.75% (Marcaine) has longer duration of action but increased risk of corneal toxicity . Intraocular lidocaine: 0.3cc of 1% isotonic nonpreserved lidocaine administered intracamerally. Onset of action 10 seconds. Reduces amount of local and IV sedation needed Intracameral non-preserved 2% Topical lidocaine gel . Topical, intracameral, local retrobulbar, peribulbar eyelid blocks lidocaine . Local anesthetics block sympathetic vascular tone and dilate blood vessels . Epinephrine added to slow vascular absorption . Topical: disrupt tight junctions interfere with corneal repair and metabolism and cannot be used for chronic pain relief . Lidocaine (Xylocaine), bupivacaine (Marcaine) . Hyaluronidase increases tissue permeability and increases dispersal of local anesthetic. Hylenex a recombinant human substitute used instead of hyaluronidase 5 4/24/2018 .Proparacaine (Alcaine, Ophthetic): least irritating, onset of action 15 seconds and lasts 20 minutes .Benoxinate oxybuprocaine (Fluress, Flurox) similar to proparacaine .Tetracaine and tetravisc: action and duration similar to proparacaine but with more extensive corneal epithelial toxicity . Patients respond well to intravenous fentanyl and midazolam (Versed) in conjunction with topical and intracameral anesthesia. “Vocal local”: calmly provide verbal instructions and reassurance and verbal guidance during the procedure. Many patients experience more anxiety when surgery is performed on their second eye. Viscoelastics . Propofol may be added IV in these instances or in general in more anxious patients. Rheological properties determine the classification, include: Dispersive to . Viscosity cohesive: . Viscoelasticity . Pseudoplasticity Dispersives, . Surface tension cohesives, . Building blocks: combination . Sodium hyaluronidate (Na HA) agents, visco- . Chondroitin sulfate(CS) adaptive . Hydroxypropyl methycellulose (HPMC) . The molecular size, weight and concentration of each determine the characteristics of the OVD 6 4/24/2018 Cohesive: higher viscosity: Dispersive: lower viscosity: coat Cohesive (Viscoat) and intraocular structure, retained when Dispersive: HPMC pressurize eye, create space injected Dispersive (Provisc) Duo Visc . Other dispersives: . Full spectrum of dispersive . Healon D, Viscoat, Ocucoat and cohesive in one syringe: . DiscoVisc and Amvisc . Other cohesives: . Healon, Healon GV, Provisc, Amvisc Plus . Other two syringe systems: . Duovisc: Viscoat and Provisc; Healon D and H; . Healon D and GV . Amvisc and Ocucoat .Soft-shell technique for New class: cataract surgery super- .Combines dispersive cohesive and cohesive OVD viscoelastic used simultaneously and provide injecting dispersive first then cohesive protection of dispersives 7 4/24/2018 .Out of the bottle .Combinations of phenylephrine, cyclogyl and tropicamide from bottle. solution soaked sponges applied to eye .Cyclomydryl gel .others Stains anterior capsule enhance Inject into eye before capsulorhexis visualization Added to irrigating solution prior to intraocular surgery Maintains pupil dilation and decreases pain Phenylephrine and ketorolac (NSAID) 8 .
Load more

Recommended publications
  • Hyperinflation Management Medications Requiring Prior Authorization for Medical Necessity
    July 2021 Effective 07/01/2021 Hyperinflation Management Medications Requiring Prior Authorization for Medical Necessity Below is a list of medicines by drug class that will not be covered without a prior authorization for medical necessity. If you continue using one of these drugs without prior approval for medical necessity, you may be required to pay the full cost. If you are currently using one of the drugs requiring prior authorization for medical necessity, ask your d octor to choose one of the generic or brand formulary options listed below. Category * Drugs Requiring Prior Formulary Options Drug Class Authorization for Medical Necessity 1 Allergies Dexchlorpheniramine levocetirizine Antihistamines Diphen Elixir (NDC^ 69067009204 only) RyClora CARBINOXAMINE TABLET 6 MG Anti-convulsants topiramate ext-rel capsule carbamazepine, carbamazepine ext-rel, (generics for QUDEXY XR only) clobazam, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, primidone, rufinamide, tiagabine, topiramate, valproic acid, zonisamide, FYCOMPA, OXTELLAR XR, TROKENDI XR, VIMPAT, XCOPRI ZONEGRAN carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, primidone, tiagabine, topiramate, valproic acid, zonisamide, FYCOMPA, OXTELLAR XR, TROKENDI
    [Show full text]
  • Ep 1931310 B1
    (19) & (11) EP 1 931 310 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/12 (2006.01) A61K 9/06 (2006.01) 06.06.2012 Bulletin 2012/23 A61K 9/70 (2006.01) A61K 47/32 (2006.01) A61K 47/24 (2006.01) A61K 47/10 (2006.01) (21) Application number: 06779420.6 (86) International application number: (22) Date of filing: 14.09.2006 PCT/GB2006/003408 (87) International publication number: WO 2007/031753 (22.03.2007 Gazette 2007/12) (54) Monophasic film-forming composition for topical administration Monophasische filmbildende Zusammensetzung zum topischen Auftrag Composition monophase formant un film pour l’administration à voie topique (84) Designated Contracting States: • JONES, Stuart, Allen AT BE BG CH CY CZ DE DK EE ES FI FR GB GR London SE3 0XA (GB) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Lord, Hilton David Marks & Clerk LLP (30) Priority: 14.09.2005 GB 0518769 90 Long Acre London (43) Date of publication of application: WC2E 9RA (GB) 18.06.2008 Bulletin 2008/25 (56) References cited: (73) Proprietor: Medpharm Limited WO-A2-01/43722 US-A- 4 752 466 Charlbury, US-A- 4 863 721 US-A1- 2004 184 994 Oxfordshire OX7 3RR (GB) US-A1- 2004 213 744 (72) Inventors: • BROWN, Marc, Barry Hertfordshire WD19 4QQ (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Meta-Xylene: Identification of a New Antigenic Entity in Hypersensitivity
    Clinical Communications Meta-xylene: identification of a new Our patient is a 53-year-old male who presented in 2003 with antigenic entity in hypersensitivity contact dermatitis after the use of lidocaine and disinfection with reactions to local anesthetics chlorhexidine. In 2006, an extensive skin testing by patch, prick, Kuntheavy Ing Lorenzini, PhDa, intradermal sampling, and graded challenge was performed as b c followed. The patch tests were performed with the thin layer Fabienne Gay-Crosier Chabry, MD , Claude Piguet, PhD , rapid use epicutaneous test, using the caine mix (benzocaine, a and Jules Desmeules, MD tetracaine, and cinchocaine), the paraben mix (methyl, ethyl, propyl, butyl, and benzylparaben), and the Balsam of Peru. The Clinical Implications caine and paraben mix were positive, and the patch test was possibly positive for Balsam of Peru. The prick test performed The authors report a patient who presented delayed with preservative-free lidocaine 20 mg/mL (Lidocaïne HCl hypersensitivity reactions to several local anesthetics, all “Bichsel” 2%, Grosse Apotheke Dr. G. Bichsel, Switzerland) was containing a meta-xylene entity, but not to articaine, negative. The intradermal test, performed with lidocaine 20 mg/ which is a thiophene derivative. Meta-xylene could be the mL containing methylparaben (Xylocain 2%, AstraZeneca, immunogenic epitope. Switzerland) with 1/10 and 1/100 dilutions, was negative. The subcutaneous challenge test was performed with 10 mg of preservative-free lidocaine 20 mg/mL (Lidocaïne HCl “Bichsel” TO THE EDITOR: 2%, Grosse Apotheke Dr. G. Bichsel) and lidocaine 20 mg/mL containing methylparaben (Lidocaïne Streuli 2%, Streuli, Hypersensitivity reactions to local anesthetics (LAs) are rare and Switzerland), both of which were positive and had the appear- represent less than 1% of all adverse reactions to LAs.
    [Show full text]
  • Local Anesthetics
    Local Anesthetics Introduction and History Cocaine is a naturally occurring compound indigenous to the Andes Mountains, West Indies, and Java. It was the first anesthetic to be discovered and is the only naturally occurring local anesthetic; all others are synthetically derived. Cocaine was introduced into Europe in the 1800s following its isolation from coca beans. Sigmund Freud, the noted Austrian psychoanalyst, used cocaine on his patients and became addicted through self-experimentation. In the latter half of the 1800s, interest in the drug became widespread, and many of cocaine's pharmacologic actions and adverse effects were elucidated during this time. In the 1880s, Koller introduced cocaine to the field of ophthalmology, and Hall introduced it to dentistry Overwiev Local anesthetics (LAs) are drugs that block the sensation of pain in the region where they are administered. LAs act by reversibly blocking the sodium channels of nerve fibers, thereby inhibiting the conduction of nerve impulses. Nerve fibers which carry pain sensation have the smallest diameter and are the first to be blocked by LAs. Loss of motor function and sensation of touch and pressure follow, depending on the duration of action and dose of the LA used. LAs can be infiltrated into skin/subcutaneous tissues to achieve local anesthesia or into the epidural/subarachnoid space to achieve regional anesthesia (e.g., spinal anesthesia, epidural anesthesia, etc.). Some LAs (lidocaine, prilocaine, tetracaine) are effective on topical application and are used before minor invasive procedures (venipuncture, bladder catheterization, endoscopy/laryngoscopy). LAs are divided into two groups based on their chemical structure. The amide group (lidocaine, prilocaine, mepivacaine, etc.) is safer and, hence, more commonly used in clinical practice.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Quick Practice Guides Index with Few Exceptions, the Quick Practice Guides in PCF Are Restricted to a Maximum of 2 Pages in Order to Facilitate Everyday Use
    PCF4_Cover_MAY.qxp 8/18/11 2:57 PM Page 2 Quick Practice Guides Index With few exceptions, the Quick Practice Guides in PCF are restricted to a maximum of 2 pages in order to facilitate everyday use. Before using them, it is important to study the associated text in order to fully understand their rationale. Page Chapter 1: Gastro-intestinal system Management of death rattle (noisy respiratory secretions) 8 Opioid-induced constipation 38 Bowel management in paraplegia and tetraplegia 40 Chapter 4: Central nervous system Depression 187 Psychostimulants in depressed patients with a short prognosis 209 Management of nausea and vomiting 225 Chapter 5: Analgesics Management of procedure-related pain 379 Use of transdermal buprenorphine 388 Use of transdermal fentanyl patches 398 Use of methadone for cancer pain 422 Chapter 6: Infections Cellulitis in lymphoedema 459 Chapter 16 Management of death rattle (noisy respiratory secretions) repeat 637 Chapter 20 Setting up a McKinley T34 syringe pump for CSCI 673 Setting up a Graseby MS16A or MS26 syringe driver for CSCI 676 Chapter 22 Administration of drugs by enteral feeding tube 700 PCF4 PALLIATIVE CARE FORMULARY This first print-run of PCF4 has been made possible, in part, by Help the Hospices, the leading charity supporting hospice care throughout the United Kingdom. www.helpthehospices.org.uk Published by palliativedrugs.com Ltd. Palliativedrugs.com Ltd Hayward House Study Centre Nottingham University Hospitals NHS Trust, City Campus Nottingham NG5 1PB United Kingdom www.palliativedrugs.com # palliativedrugs.com Ltd 2011 The moral rights of the editors have been asserted. PCF3 2007, reprinted 2008, 2009 PCF2 2002, reprinted 2003 PCF1 1998 All rights reserved.
    [Show full text]
  • Topical Pain Management Order Form
    Topical Pain Management Order Form Patient Name:______________________________________ Doctor Name: ________________________________________ Address: _______________________________________ Address: _______________________________________ City: ______________State: __________ Zip: ___________ City: _________________ State: ______ Zip: _________ DOB: ________________ Allergies: ___________________ DEA# ________________ NPI # ___________________ Phone Number: ( ) ______________________________ Ofce Phone: ( ) ______________ Contact: _____________ New Patients: Fax current insurance information with Rx COMMON FORMULATIONS: * NOTE: CROSS OUT ANY UNWANTED MEDICATIONS IF NOT DESIRED * ANTI-INFLAMMATORY CREAMS _____ CASCADE DICLOFENAC 3% BACLOFEN 2% (CDB ) For (ARTHRITIS-TENDONITIS-PLANTAR FASCITIS-EPICONDYLITIS) _____ CASCADE DICLOFENAC 3% BACLOFEN 2% CYCLOBENZ, 2% TETRACAINE 2% (BCDT) (MUSCULOSKELETAL) NEUROPATHIC PAIN CREAMS **NOTE: KETAMINE IS CONTROLLED SCHEDULE III, SUBSTITUTE AMANTADINE 8%, IF DESIRED. _____ KETAMINE 10%-BACLOFEN 2%-CYCLOBENZAPRINE 2%-GABAPENTIN 6%-LIDOCAINE 5% (KBCGL) _____ KETAMINE 10%-CLONIDINE 0.2%-GABAPENTIN 6%-IMIPRAMINE 3%-MEFENAMIC ACID 3%-TETRACAINE 2% (KCGIMT) CREAM (RSD/CRPS-TRIGEMINAL NEURALGIA-PHANTOM LIMB PAIN-DEVELOPING NEUROPATHY) _____ KETAMINE 10%-BACLOFEN 2%-GABAPENTIN 6%-IMIPRAMINE 3%-NIFEDIPINE 2%-TETRACAINE 2% (KBGINT) ( DIABETIC & CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY) COMBINATION PAIN CREAMS _____ DICLOFENAC 3%-BACLOFEN 2%-CYCLOBENZAPRINE 2%-GABAPENTIN 6%-TETRACAINE 2% (DBCGT) (TMJ, MUSCULOSKELETAL
    [Show full text]
  • A Brief History Behind the Most Used Local Anesthetics
    Tetrahedron xxx (xxxx) xxx Contents lists available at ScienceDirect Tetrahedron journal homepage: www.elsevier.com/locate/tet Tetrahedron report XXX A brief history behind the most used local anesthetics * Marco M. Bezerra, Raquel A.C. Leao,~ Leandro S.M. Miranda, Rodrigo O.M.A. de Souza Biocatalysis and Organic Synthesis Group, Chemistry Institute, Federal University of Rio de Janeiro, 21941-909, Brazil article info abstract Article history: The chemistry behind the discovery of local anesthetics is a beautiful way of understanding the devel- Received 13 April 2020 opment and improvement of medicinal/organic chemistry protocols towards the synthesis of biologically Received in revised form active molecules. Here in we present a brief history based on the chemistry development of the most 16 September 2020 used local anesthetics trying to draw a line between the first achievements obtained by the use of Accepted 18 September 2020 cocaine until the synthesis of the mepivacaine analogs nowadays. Available online xxx © 2020 Elsevier Ltd. All rights reserved. Keywords: Anesthetics Medicinal chemistry Organic synthesis Mepivacaíne Contents 1. Introduction . ............................. 00 1.1. Pain and anesthesia . ............................................... 00 1.2. Ancient techniques to achieve anesthesia . ............................... 00 1.3. The objective of this work . .......................................... 00 2. Cocaine .............................................................................................. ............................
    [Show full text]
  • CTY-5339A Cheek Safety Final.Pdf
    Clinical Therapeutics/Volume ], Number ], 2017 Lack of Methemoglobin Elevations After Topical Applications of Benzocaine Alone or Benzocaine Plus Tetracaine to the Oral Mucosa Steven Wang, DMD, MD, MPH1; Helen Giannakopoulos, DDS, MD1; Jamie Lowstetter, BS1; Laura Kaye, BS1; Catherine Lee, BS1; Stacey Secreto, CCRC1; Vanessa Ho1; Matthew C. Hutcheson, MS2; John T. Farrar, MD, PhD3; Ping Wang, PhD3; Geraldine Doyle, PhD4; Stephen A. Cooper, DMD, PhD5; and Elliot V. Hersh, DMD, MS, PhD1 1University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania; 2Tegra Analytics, Doylestown, Pennsylvania; 3University of Pennsylvania Pearlman School of Medicine, Philadelphia, Pennsylvania; 4Geraldine Doyle, PhD, LLC, Chatham, New Jersey; and 5Stephen A. Cooper DMD, PhD, LLC, Palm Beach Gardens, Florida ABSTRACT Key words: benzocaine, methemoglobinemia, Purpose: This study evaluated changes in methe- tetracaine, topical anesthetics. moglobin and oxygen saturation concentrations after the administration of recommended doses of 14% benzocaine alone or 14% benzocaine combined with 2% tetracaine. INTRODUCTION Methods: American Society of Anesthesiology class Drug-induced methemoglobinemia is a potentially life- ¼ 1 and 2 subjects (n 40) were enrolled in this threatening event that typically involves overdoses of fi – modi ed crossover study. Subjects were administered strong oxidizing drugs1 6 (Table). These drugs can 0.2 mL of 14% benzocaine alone, 0.2 mL of 14% convert the reduced form of hemoglobin (Feþþ), benzocaine plus 2% tetracaine, or 0.4 mL of 14% which readily carries and releases oxygen to tissues, benzocaine plus 0.2% benzocaine to their cheek to methemoglobin (Feþþþ).6 Methemoglobin does mucosa. Venous blood (5 mL) was drawn from the not readily bind oxygen, and when it does, it does not antecubital fossa before and 60 minutes after drug readily release it to tissues.1 Healthy adults typically application for methemoglobin analyses.
    [Show full text]
  • Food and Drug Administration, HHS § 524.86
    Food and Drug Administration, HHS § 524.86 524.981b Fluocinolone acetonide solution. 524.1484k Neomycin sulfate, prednisolone, 524.981c Fluocinolone acetonide, neomycin tetracaine, and squalane topical-otic sus- sulfate cream. pension. 524.981d Fluocinolone acetonide, dimethyl 524.1580 Nitrofurazone ophthalmic and top- sulfoxide solution. ical dosage forms. 524.981e Fluocinolone acetonide, dimethyl 524.1580a [Reserved] sulfoxide otic solution. 524.1580b Nitrofurazone ointment. 524.1005 Furazolidone aerosol powder. 524.1580c Nitrofurazone soluble powder. 524.1044 Gentamicin sulfate ophthalmic and 524.1580d [Reserved] topical dosage forms. 524.1580e Nitrofurazone ointment with buta- 524.1044a Gentamicin ophthalmic solution. caine sulfate. 524.1044b Gentamicin sulfate, 524.1600 Nystatin ophthalmic and topical betamethasone valerate otic solution. dosage forms. 524.1044c Gentamicin ophthalmic ointment. 524.1600a Nystatin, neomycin, thiostrepton, 524.1044d Gentamicin sulfate, and triamcinolone acetonide ointment. betamethasone valerate ointment. 524.1600b Nystatin, neomycin, thiostrepton, 524.1044e Gentamicin sulfate spray. and triamcinolone acetonide ophthalmic 524.1044f Gentamicin sulfate, ointment. betamethasone valerate topical spray. 524.1662 Oxytetracycline hydrochloride oph- 524.1044g Gentamicin sulfate, thalmic and topical dosage forms. betamethasone valerate, clotrimazole 524.1662a Oxytetracycline hydrochloride and ointment. hydrocortisone spray. 524.1044h Gentamicin sulfate, mometasone 524.1662b Oxytetracycline hydrochloride, furoate,
    [Show full text]
  • 4160-01-P Department of Health and Human Services
    This document is scheduled to be published in the Federal Register on 02/27/2014 and available online at http://federalregister.gov/a/2014-01958, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 524, 526, and 529 [Docket No. FDA-2014-N-0002] New Animal Drugs; Change of Sponsor AGENCY: Food and Drug Administration, HHS. ACTION: Final rule; technical amendments. SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 54 approved new animal drug applications (NADAs) and 1 approved abbreviated new animal drug application (ANADA) for topical, intramammary, and certain other dosage form new animal drug products from Pfizer, Inc., including its several subsidiaries and divisions, to Zoetis, Inc. DATES: This rule is effective [INSERT DATE OF PUBLICATION IN THE FEDERAL REGISTER]. FOR FURTHER INFORMATION CONTACT: Steven D. Vaughn, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855; 240-276-8300, [email protected]. SUPPLEMENTARY INFORMATION: Pfizer, Inc., 235 E. 42d St., New York, NY 10017, and its wholly owned subsidiaries Alpharma, LLC; Fort Dodge Animal Health, Division of Wyeth; Fort Dodge Animal Health, Division of Wyeth Holdings Corp.; and its division, Pharmacia & Upjohn Co., have informed FDA that they have transferred ownership of, and all rights and 2 interest in, the 54 approved NADAs and 1 approved ANADA in table 1 to Zoetis, Inc., 333 Portage St., Kalamazoo, MI 49007. Table 1.--NADAs and ANADA transferred from Pfizer, Inc., to Zoetis, Inc.
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]